Selected Abstracts from the January Issue of the Journal of Vascular Surgery  by unknown
ABSTRACTSSelected Abstracts from the January Issue of the Journal of Vascular
Surgery*
Editors: Anton N. Sidawy and Bruce A. PerlerThe BASIL survival prediction model in patients with
peripheral arterial disease undergoing revascularization
in a university hospital setting and comparison with the
FINNVASC and modiﬁed PREVENT scores
Paul W. Moxey, Jack Brownrigg, Sharanya S. Kumar, Geor-
gina Crate, Peter J. Holt, Matt M. Thompson, Keith G. Jones,
Robert J. Hinchliffe
Background: Critical limb ischemia carries a signiﬁcant risk
of morbidity and mortality. The development of scores to
predict risk can aid clinical decision making. The Bypass
versus Angioplasty in Severe Ischaemia of the Leg (BASIL)
trial investigators developed a model to predict death,
which has not been previously validated.
Methods: Data were collected in a prospectively maintained
database on all patients who underwent angioplasty or arte-
rial bypass for peripheral artery disease in a university hospital
between January 2008 and June 2010. The main outcome
measures were all-cause mortality and amputation-free
survival at 3, 6, 12, and 24 months after the index interven-
tion. The BASIL survival predictor, Finland National Vascular
(FINNVASC) registry, and Edifoligide for the Prevention of
Infrainguinal Vein Graft Failure (PREVENT) models were
applied and receiver-operating characteristic (ROC) curve
analysis was used to evaluate their predictive power.
Results: Data on 342 patients were collected. Patients with
isolated iliac disease or claudication were excluded. The 6-,
12-, and 24-month all-cause mortality rates were 11.6%,
17.9%, and 26.8%, respectively. The area under the ROC
curve (95% conﬁdence interval) using the BASIL score to
predict mortality at 6, 12, and 24 months was 0.700 (0.60-
0.80; P < .001), 0.651 (0.56-0.74; P < .003), and 0.681 (0.59-
0.74; P < .001), respectively. ROC curve analysis indicated
that the performance of the BASIL score in this cohort was
comparable to other validated predictive scores.
Conclusions: The BASIL survival prediction model can
moderately predict short-term and medium-term mortality
in patients with limb ischemia and may be a useful adjunct
to decision making in everyday clinical practice.Early (30-day) vein remodeling is predictive of midterm
graft patency after lower extremity bypass
Warren J. Gasper, Christopher D. Owens, Ji Min Kim, Nancy
Hills, Michael Belkin, Mark A. Creager, Michael S. Conte*Full articles available online at www.jvascsurg.org
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http://dx.doi.org/10.1016/S1078-5884(12)00825-8Objective: Successful adaptation of a vein graft to an
arterial environment is incompletely understood. We
sought to investigate whether early vein graft remodeling is
predictive of subsequent patency.
Methods: A prospective longitudinal study was conducted
of 67 patients undergoing lower extremity bypass with
autogenous vein between February 2004 and April 2008.
Preoperative blood samples were drawn for biomarkers.
During the bypass operation, a 5-cm index segment of
the graft was registered for serial lumen diameter
measurements at 0, 1, 3, 6, 9, and 12 months using
duplex ultrasound imaging. The imaging substudy analysis
included patients with at least two ultrasound
assessments.
Results: Patients (55% male) were a median age of 70 years
(interquartile range [IQR], 59-76 years), 40% had diabetes
mellitus, 49% had critical limb ischemia, 75% were taking
a statin, and 91% were taking an antiplatelet medication.
Median follow-up was 32 months (IQR, 15-47 months). The
median baseline high-sensitivity C-reactive protein level
(hsCRP) was 3.2 mg/L (IQR, 1.4-9.7 mg/L). The average
intraoperative, postimplantation vein lumen diameter was
3.9 ± 1.0 mm, increasing to 4.7 ± 1.1 mm at 1 month, an
average 24% ± 27% change per patient. By 3 months, the
average lumen diameter was 5.1 ± 1.6 mm, with little
subsequent change observed to 12 months. Nonwhite race,
baseline hsCRP 5 mg/L, statin use, and initial lumen
diameter were signiﬁcantly associated with early (0- to 1-
month) vein remodeling in a multivariable regression
model. The primary patency rate for the cohort was 60% ±
6.3% at 2 years. Initial lumen diameter of the index segment
was not associated with primary patency, whereas larger
lumen diameter achieved at 1 month (5.1 mm) was
positively associated with primary patency (log-rank, P =
.03). Early (30-day) remodeling behavior was used to divide
patients into “poor remodelers” (<5% lumen diameter
change, n = 6), “modest remodelers” (5% to 25% change,
n = 29), and “robust remodelers” (>+25% change, n = 30).
Early remodeling category was signiﬁcantly associated with
primary patency rate at 2 years (log-rank, P = .02). A
multivariable Cox proportional hazards model showed that
modest remodelers (hazard ratio, 3.9; 95% conﬁdence
interval, 1.02-15; P = .04) and poor remodelers (hazard
ratio, 13; 95% conﬁdence interval; P = .008) had signiﬁcantly
higher hazard ratios for graft failure than robust early
remodelers.
Conclusions: Early remodeling of the arterialized vein
appears to predict midterm bypass graft patency. In
addition to baseline diameter, race, inﬂammation, hsCRP,
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eling, but the mechanisms for these observations are not
understood.Mortality in patients with premature lower extremity
atherosclerosis
Hamza Rana, Jeanette S. Andrews, Billy G. Chacko, Kim-
berley J. Hansen, Pavel J. Levy
Objective: Lower extremity peripheral artery disease
occurs mostly in the elderly and is associated with high
mortality. Limited data are available regarding long-term
mortality in patients with premature lower extremity
atherosclerosis (PLEA). Our objective was to determine the
all-cause mortality and its predictors in younger PLEA
patients.
Methods: We studied patients with severe PLEA who
were <55 years of age at diagnosis and treated at
a single academic vascular center between 1998 and
2010. Data were collected prospectively at the initial
evaluation for vascular care. National Death Index and
hospital records were used to determine all-cause
mortality. Demographic and clinical characteristics were
summarized using count (%), mean (standard deviation),
or median (interquartile range), and associations with
aspirin use were tested using c2 test, t-test, or Wilcoxon
test. Survival times were estimated using Kaplan-Meier
estimates, and associations with covariates were tested
using simple and multivariable Cox proportional hazards
models.
Results: A total of 564 patients were analyzed (46%
female; 20% nonwhite; mean age 49.4 [6.4] years). Ninety-
ﬁve percent of patients had 2 cardiovascular risk factors,
31% had coronary artery disease (CAD), and 10% had
a history of cancer. During median follow-up of 5.6 years
(interquartile range, 2.3-8.3 years), 108 deaths (19%) were
recorded. Two-year estimated mortality (standard error)
was 6% (0.01), and 5-year estimated mortality was 16%
(0.02). In univariate regression analysis, patient age (P ¼
.04), prior amputation (P < .01), history of cancer (P ¼
.03), and established CAD (P ¼ .04) were associated with
increased risk of mortality. Aspirin use and lipid-lowering
therapy at the time of ﬁrst evaluation were associated
with improved survival (P < .01 and P ¼ .02, respectively).
A multivariable Cox proportional hazards model identiﬁed
age (hazard ratio [HR] for 5-year increase, 1.17; 95% CI,
1.01-1.36; P ¼ .04), prior amputation (HR, 1.99; 95% CI,
1.18-3.34; P ¼ .01), history of cancer (HR, 2.35; 95% CI,
1.36-4.07; P < .01), and CAD (HR, 1.76; 95% CI, 1.16-2.67;
P < .01) as independent predictors of mortality in patients
with PLEA. Importantly, history of aspirin use had a signif-
icant protective effect (HR, 0.45; 95% CI, 0.30-0.69; P <
.01). The impact of lipid-lowering therapy was no longer
signiﬁcant in multivariable modeling.
Conclusions: Patients with PLEA demonstrate high all-cause
mortality. No traditional cardiovascular risk factors pre-
dicted mortality. Aspirin therapy at the time of ﬁrstevaluation was a signiﬁcant and independent predictor of
improved survival in patients with PLEA.Computed tomography angiography-based evaluation of
great saphenous vein conduit for lower extremity bypass
Dorian J. deFreitas, Timothy P. Love, Karthikeshwar Kasir-
ajan, Noel C. Haskins, Ronald T. Mixon, Luke P. Brewster,
Yazan Duwayri, Matthew A. Corriere
Objective: Lower extremity computed tomography angiog-
raphy (CTA) is frequently used for anatomic assessment of
lower extremity peripheral arterial disease. When lower
extremity bypass is planned, duplex ultrasound (DUS) is
routinely obtained to evaluate the great saphenous vein
(GSV) for use as conduit. Although GSV can be visualized on
CTA images, diameter assessment is not routinely included
in formal study interpretation. We hypothesized that CTA
images could be used to measure GSV diameters and that
CTA-based diameters would correlate with measurements
obtained using DUS.
Methods: Consecutive patients undergoing lower
extremity arterial bypass who were evaluated preopera-
tively with both CTA and DUS vein mapping were identi-
ﬁed at a single hospital. Minimum above- and below-knee
GSV diameters were measured from electronically archived
CTA images by two independent observers. CTAs were
performed using standard arterial phase protocol without
additional venous phase imaging. Between-observer
reproducibility of CTA-based diameter measurements was
evaluated using intraclass correlation coefﬁcients. Corre-
lation between CTA and DUS-based GSV diameters was
evaluated with Spearman correlation coefﬁcients. CTA
diameter cut-points for identiﬁcation of adequate GSV
bypass conduit, deﬁned as DUS-based minimum GSV
diameter  3 mm, were determined using receiver-oper-
ating characteristic curves.
Results: Sixty-three lower extremities were evaluated in 36
patients. In the absence of previous surgical removal, GSV
was visible on all CTAs reviewed. No instances of GSV
thrombosis were identiﬁed on DUS. Minimum DUS-based
above-knee GSV diameter was 2.9 ± 0.1 mm (range, 1.4-4.6
mm), and mean below-knee diameter was 2.6 ± 0.1 mm
(range, 1.3-4.0 mm). When GSV was visible and exceeded
the minimum diameter threshold for CTA measurement,
correlation between CTA- and DUS-based diameters was
both positive and highly signiﬁcant (ρ = 0.595; P < .0001).
CTA-based diameters also had excellent reliability between
observers (r [95% CI]: 0.88 [0.85-0.91]). For identiﬁcation of
adequate bypass conduit using CTA, above-knee GSV
diameter  3.9 mm was 67% sensitive and 73% speciﬁc;
below-knee GSV diameter 3.0 mm was 75% sensitive and
84% speciﬁc.
Conclusions: CTA-based GSV diameter measurements have
good reproducibility and highly signiﬁcant correlation with
DUS-based diameters. CTA-based GSV diameter is
a speciﬁc but relatively insensitive indicator of adequate
bypass conduit. When CTA-based diameters indicate
Abstracts 95inadequate GSV bypass conduit, conﬁrmatory DUS vein
mapping is warranted. Conﬁrmatory DUS vein mapping
may be unnecessary when adequate vein diameter is
identiﬁed on CTA.Aneurysm-osteoarthritis syndrome with visceral and iliac
artery aneurysms
Denise van der Linde, Hence J.M. Verhagen, Adriaan
Moelker, Ingrid M.B.H. van de Laar, Isabelle Van Herzeele,
Julie De Backer, Harry C. Dietz, Jolien W. Roos-Hesselink
Objective: Aneurysms-osteoarthritis syndrome (AOS),
caused by SMAD3 mutations, is a recently described auto-
somal-dominant syndrome characterized by arterial aneu-
rysms, tortuosity, and aortic dissections in combination with
osteoarthritis. Our objective was to evaluate the AOS-
related vascular consequences in the visceral and iliac
arteries and raise awareness for this aggressive syndrome
among vascular specialists.
Methods: All AOS patients were monitored regularly
according to our clinical AOS protocol. The study included
those with one or more visceral aneurysms or tortuosity, or
both. Clinical and surgical data were obtained from record
abstraction.
Results: The study included 17 AOS patients (47% men)
aged 47 ± 13 years. A total of 73 aneurysms were
encountered, of which 46 were located in the abdomen.
The common iliac artery was most commonly affected
(37%), followed by the superior mesenteric artery (15%),
celiac trunk (11%), and splenic artery (9%). Rapid aneurysm
growth 1 year was found in three arteries (gastric,
hepatic, and vertebral artery). Furthermore, arterial tortu-
osity was noted in 94% of patients. Four patients under-
went six elective (endo) vascular interventions for
aneurysms in the iliac, hepatic, gastric, or splenic artery,
without major perioperative or postoperative
complications.
Conclusions: AOS predisposes patients to widespread
visceral and iliac artery aneurysms and extreme arterial
tortuosity. Early elective aneurysm repair should be
considered because the risk of aneurysm rupture is esti-
mated to be very high and elective (endo) vascular inter-
ventions were not complicated by fragility of arterial tissue.
Given the aggressive behavior of AOS, it is of utmost
importance that vascular specialists are aware of this new
syndrome.A preliminary study of cognitive outcome differences on
the side of carotid artery stenting
Hideyuki Ishihara, Fumiaki Oka, Satoshi Shirao, Shoichi Kato,
Hirokazu Sadahiro, Masami Osaki, Michiyasu Suzuki
Objective: The right and left sides of the brain play different
roles in cognition. Therefore, the side of treatment should be
taken into consideration when evaluating cognitive outcome
following revascularization. Thus, we designed a study toevaluate changes in right hemisphere cognitive function in
patients undergoing right carotid artery stentings (CAS) and
left hemispheric cognitive function in patients undergoing
left CAS. In addition, we studied CAS-related changes in
regional cerebral blood ﬂow to determine potential corre-
lations with changes in cognitive function.
Methods:We performed a prospective assessment of 39 CAS
patients, all of whom were right-handed. Patients with
contralateral stenotic lesions were excluded. Twenty-one
patients underwent CAS of the right internal carotid artery
(Right CAS group) and 18 underwent CAS of the left internal
carotid artery (Left CAS group). Neuropsychological testing
was performed preoperatively and 6 months after endovas-
cular treatment. Cerebral blood ﬂowwas determined by 123I-
labeled N-isopropyl-p-iodoamphetamine single-photon emis-
sion computed tomography before and 6 months after CAS.
Results: In the Right CAS group, postoperative performance
intelligence quotient score (91.1 ± 18.2) was signiﬁcantly
improved compared with the preoperative score (84.9 ±
16.7; P < .001). In the Left CAS group, postoperative verbal
intelligence quotient score (104.0 ± 18.8) was signiﬁcantly
higher than that before endovascular treatment (97.9 ±
15.8; P < .005). Postoperative regional cerebral blood ﬂow
was not signiﬁcantly different from that before endovas-
cular treatment in either group. However, regional cere-
brovascular reactivity of the treated side showed signiﬁcant
improvement after treatment.
Conclusions: Amelioration of cognitive function may be
dependent on the side of revascularization. Performance
intelligence quotient improved after CAS in patients with
severe carotid artery stenosis on the right side. Verbal
intelligence quotient also improved on the left side after
endovascular treatment. These effects seemed to involve
improvement in regional cerebrovascular reactivity by CAS.Endograft salvage of hemodialysis accesses threatened by
pseudoaneurysms
Alison J. Kinning, Russell W. Becker, Gregory J. Fortin, Robert
G. Molnar, Carlo A. Dall’Olmo
Objective: Currently, no formal practice guidelines exist
regarding the use of endografts to exclude hemodialysis
access pseudoaneurysms and prolong access lifespan in
dialysis patients. We evaluated the efﬁcacy of percutaneous
endograft placement for exclusion of hemodialysis access
pseudoaneurysms.
Methods: Between July 2005 and October 2009, 32 patients
were prospectively evaluated. Twenty-four patients were
actively enrolled in the study based upon clinical and ultra-
sonographic evaluation of their hemodialysis accesses. Self-
expanding covered endografts were placed percutaneously
to exclude access pseudoaneurysms. Patients were evaluated
at 2 and 6 months to assess for graft patency, access or
outﬂow stenosis, endoleak, or stent graft migration.
Results: No procedural complications resulted from these
interventions. An average of 1.8 endografts was placed per
patient, with patients requiring between 1 and 3 endografts
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83% at completed 2-month follow-up and 54% at 6-month
follow-up. At 12 months, primary-assisted patency was 50%.
Eleven patients left the study before 6-month follow-up:
ﬁve (21%) required explantation secondary to infection
between 1 and 4 months; three (13%) were lost to follow-
up; two (8%) died of unrelated causes; and 1 requested
explantation citing pain from the “stent poking the vein.”
Mean time to explantation secondary to infection was 2.4
months. Mean duration of patency was 17.6 months with
a range from 0 to 76 months. Mean duration of patency for
patients who completed 6-month follow-up was 28.7
months. The longest duration of patency is 6 years 4
months, after stent fracture and subsequent placement of
a new stent at 6 years 2 months. One other incident of stent
fracture occurred at 36 months. Dialysis patterns were not
interrupted in either patient.
Conclusions: The long-term results demonstrate that
endograft salvage of failing hemodialysis accesses is a viable
and safe alternative to open surgical revision that excludes
pseudoaneurysms while maintaining uninterrupted access
patency. A larger sample size and longer follow-up are
needed to support the study data.Hospital morbidity rankings and complication severity in
vascular surgery
Micah E. Girotti, Clifford Y. Ko, Justin B. Dimick
Introduction: The American College of Surgeons National
Surgical Quality Improvement Program ranks hospitals
according to risk-adjusted rates of postoperative complica-
tions. However, this approach does not consider the
severity or number of complications that occurred. Wesought to determine whether incorporating this information
would alter hospital rankings.
Methods: The study examined data for the 39,519 patients
who underwent major vascular surgery in 206 National
Surgical Quality Improvement Program hospitals during
2008 to 2009. We categorized postoperative complications
as minor or severe and evaluated the extent to which minor
and severe complications increased a patient's risk of death
and prolonged length of stay. We then ranked hospitals on
two alternative approaches that included severity or
number of complications. We determined the effect of
these alternative methods by assessing the proportion of
hospitals that moved out of the top and bottom 20% of
hospitals compared with standard rankings.
Results: Compared with patients with minor complications,
patients with severe complications had a higher mortality
rate (16.2% vs 3.6%; P < .001) and prolonged length of stay
(66.7% vs 53.3%; P < .001). Patients with two or more
complications also had a highermortality rate (23.7% vs 6.0%;
P < .001) and prolonged length of stay (77.0% vs 50.1%; P <
.001) than patients with only one complication. Compared
with the current approach for assessing morbidity, ranking
hospitals by severe complications resulted in 12 hospitals
(29%) moving out of the top 20% and 10 hospitals (24%)
moving out of the bottom 20%. A similar degree of reclassi-
ﬁcation was found when the current rankings were compared
with an alternative approach that considered the number of
different complications.
Conclusions: Although the severity and number of post-
operative complications affect mortality and length of stay,
and subsequently, hospital rankings, existing measurement
systems do not take this into account. Quality measurement
platforms should consider weighting complications accord-
ing to severity and number.
